EAM
CRDF icon

Eventide Asset Management’s Cardiff Oncology CRDF Stock Holding History

Eventide Asset Management’s Portfolio CRDF Stock Details CRDF Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-1,467,922
Closed -$3.64M – 140
2022
Q1 		$3.64M Sell
1,467,922
-202,477
-12% -$716K 0.06% 128
2021
Q4 		$10M Hold
1,670,399
– – 0.13% 113
2021
Q3 		$11.1M Sell
1,670,399
-1,905,435
-53% -$12M 0.15% 121
2021
Q2 		$23.8M Buy
3,575,834
+1,792,346
+100% +$15.2M 0.32% 83
2021
Q1 		$16.5M Buy
+1,783,488
New +$21.7M 0.24% 98

Other funds holding CRDF

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Eventide Asset Management's CRDF Position: Q2 2022 in Review

Eventide Asset Management sold out of Cardiff Oncology (CRDF) in Q2 2022, closing a stake of 1,467,922 shares — an estimated $3.64M sold.

Eventide Asset Management first reported a position in CRDF in Q1 2021 and held it in 5 quarters. The position peaked at $23.8M in Q2 2021. 67 funds tracked by Wall St. Rank hold CRDF as of Q2 2022.

  • Eventide Asset Management reported no remaining Cardiff Oncology position as of Q2 2022 after selling out during the quarter.
  • Eventide Asset Management sold 1,467,922 Cardiff Oncology shares in Q2 2022, an estimated $3.64M.
  • Eventide Asset Management first reported a position in Cardiff Oncology in Q1 2021 and held it in 5 quarters.
  • Eventide Asset Management's Cardiff Oncology position peaked at $23.8M in Q2 2021.
  • 67 funds tracked by Wall St. Rank held Cardiff Oncology as of Q2 2022.

Based on Eventide Asset Management's 13F filing for Q2 2022, filed 15 Aug 2022.